Literature DB >> 17435899

Lobectomy for treating bronchial carcinoma: analysis of comorbidities and their impact on postoperative morbidity and mortality.

Pablo Gerardo Sánchez1, Giovani Schirmer Vendrame, Gabriel Ribeiro Madke, Eduardo Sperb Pilla, José de Jesus Peixoto Camargo, Cristiano Feijó Andrade, José Carlos Felicetti, Paulo Francisco Guerreiro Cardoso.   

Abstract

OBJECTIVE: To analyze the impact that comorbidities have on the postoperative outcomes in patients submitted to lobectomy for the treatment of bronchial carcinoma.
METHODS: A retrospective study of 493 patients submitted to lobectomy for the treatment of bronchial carcinoma was conducted, and 305 of those patients met the criteria for inclusion in the final study sample. The surgical technique used was similar in all cases. The Torrington-Henderson scale and the Charlson scale were used to analyze comorbidities and to categorize patients into groups based on degree of risk for postoperative complications or death.
RESULTS: The postoperative (30-day) mortality rate was 2.9%, and the postoperative complications index was 44%. Prolonged air leakage was the most common complication (in 20.6%). The univariate analysis revealed that gender, age, smoking, neoadjuvant therapy and diabetes all had a significant impact on the incidence of complications. The factors found to be predictive of complications were body mass index (23.8 +/- 4.4), forced expiratory volume in one second (74.1 +/- 24%) and the ratio between forced expiratory volume in one second and forced vital capacity (0.65 +/- 0.1). The scales employed proved efficacious in the identification of the risk groups, as well as in drawing correlations with morbidity and mortality (p = 0.001 and p < 0.001). In the multivariate analysis, body mass index and the Charlson index were found to be the principal determinants of complications. In addition, prolonged air leakage was found to be the principal factor involved in mortality (p = 0.01).
CONCLUSION: Reductions in forced expiratory volume in one second, in the ratio between forced expiratory volume in one second and forced vital capacity, and in body mass index, as well as a Charlson score of 3 or 4 and a Torrington-Henderson score of 3, were associated with a greater number of postoperative complications in patients submitted to lobectomy for the treatment of bronchial carcinoma. Air leakage was found to be strongly associated with mortality.

Entities:  

Mesh:

Year:  2006        PMID: 17435899     DOI: 10.1590/s1806-37132006000600005

Source DB:  PubMed          Journal:  J Bras Pneumol        ISSN: 1806-3713            Impact factor:   2.624


  9 in total

Review 1.  The anticipation and management of air leaks and residual spaces post lung resection.

Authors:  Michael Rolf Mueller; Beatrice A Marzluf
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

2.  Imbalance in redox status is associated with tumor aggressiveness and poor outcome in lung adenocarcinoma patients.

Authors:  Leonardo Lisbôa da Motta; Carolina B Müller; Marco A De Bastiani; Guilherme A Behr; Fernanda S França; Ricardo F da Rocha; Juliane B Minotto; Rosalva T Meurer; Marilda C Fernandes; Adriana Roehe; Melissa M Markoski; Cristiano F Andrade; Mauro A A Castro; Fábio Klamt
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-22       Impact factor: 4.553

3.  The potential role of extracellular regulatory kinase in the survival of patients with early stage adenocarcinoma.

Authors:  Simone de Leon Martini; Carolina Beatriz Müller; Rosalva Thereza Meurer; Marilda da Cruz Fernandes; Rodrigo Mariano; Mariel Barbachan E Silva; Fábio Klamt; Cristiano Feijó Andrade
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

4.  Non-small cell lung cancer in never smokers: a clinical entity to be identified.

Authors:  Ilka Lopes Santoro; Roberta Pulcheri Ramos; Juliana Franceschini; Sergio Jamnik; Ana Luisa Godoy Fernandes
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

Review 5.  Lung cancer in Brazil.

Authors:  Luiz Henrique Araujo; Clarissa Baldotto; Gilberto de Castro; Artur Katz; Carlos Gil Ferreira; Clarissa Mathias; Eldsamira Mascarenhas; Gilberto de Lima Lopes; Heloisa Carvalho; Jaques Tabacof; Jeovany Martínez-Mesa; Luciano de Souza Viana; Marcelo de Souza Cruz; Mauro Zukin; Pedro De Marchi; Ricardo Mingarini Terra; Ronaldo Albuquerque Ribeiro; Vladmir Cláudio Cordeiro de Lima; Gustavo Werutsky; Carlos Henrique Barrios
Journal:  J Bras Pneumol       Date:  2018 Jan-Feb       Impact factor: 2.624

6.  Efficacy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in evaluating lung cancer recurrence.

Authors:  Nobuhiro Asai; Yoshihiro Ohkuni; Kazufusa Shoji; Norihiro Kaneko
Journal:  J Bras Pneumol       Date:  2013 Mar-Apr       Impact factor: 2.624

7.  Morbidity, mortality, and categorization of the risk of perioperative complications in lung cancer patients.

Authors:  Fabiana Stanzani; Denise de Moraes Paisani; Anderson de Oliveira; Rodrigo Caetano de Souza; João Aléssio Juliano Perfeito; Sonia Maria Faresin
Journal:  J Bras Pneumol       Date:  2014 Jan-Feb       Impact factor: 2.624

8.  Anatomic pulmonary resection by video-assisted thoracoscopy: the Brazilian experience (VATS Brazil study).

Authors:  Ricardo Mingarini Terra; Thamara Kazantzis; Darcy Ribeiro Pinto-Filho; Spencer Marcantonio Camargo; Francisco Martins-Neto; Anderson Nassar Guimarães; Carlos Alberto Araújo; Luis Carlos Losso; Mario Claudio Ghefter; Nuno Ferreira de Lima; Antero Gomes-Neto; Flávio Brito-Filho; Rui Haddad; Maurício Guidi Saueressig; Alexandre Marcelo Rodrigues Lima; Rafael Pontes de Siqueira; Astunaldo Júnior de Macedo E Pinho; Fernando Vannucci
Journal:  J Bras Pneumol       Date:  2016 May-Jun       Impact factor: 2.624

9.  Risk factors for postoperative pulmonary complications and prolonged hospital stay in pulmonary resection patients: a retrospective study.

Authors:  Clovis T Bevilacqua Filho; André P Schmidt; Elaine A Felix; Fabiana Bianchi; Fernanda M Guerra; Cristiano F Andrade
Journal:  Braz J Anesthesiol       Date:  2021-02-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.